A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease
Status:
Withdrawn
Trial end date:
2020-06-16
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of ABBV-0805 in adult participants with
Parkinson's Disease and results from it will help guide the design of future clinical
studies. ABBV-0805 is administered every 28 days by intravenous (IV) infusion.